Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BION.SW
- Price
- 48.40
- Stock movement down
- -0.55 (-1.14%)
- Company name
- BB Biotech AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.64B
- Ent value
- 2.64B
- Price/Sales
- -
- Price/Book
- 1.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 56.74%
- Trailing P/E
- -
- Forward P/E
- 9.75
- PEG
- -
- EPS growth
- -35.32%
- 1 year return
- 25.59%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-19
DIVIDENDS
BION.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 6.06 |
| Price to FCF | 6.83 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.43 |
| EV to Sales | -14.98 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.15M |
| EPS (TTM) | -8.01 |
| FCF per share (TTM) | 7.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -176.15M |
| Gross profit (TTM) | -176.15M |
| Operating income (TTM) | -52.06M |
| Net income (TTM) | -438.69M |
| EPS (TTM) | -8.01 |
| EPS (1y forward) | 4.91 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | 29.55% |
| Profit margin (TTM) | 249.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.16M |
| Net receivables | 0.00 |
| Total current assets | 1.84B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.84B |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.43M |
| Total liabilities | 2.43M |
| Shareholder's equity | 1.84B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 435.73M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 386.65M |
| Dividends paid (TTM) | 219.38M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -23.81% |
| Return on Assets | -23.78% |
| Return on Invested Capital | -23.81% |
| Cash Return on Invested Capital | 20.99% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 47.95 |
| Daily high | 48.05 |
| Daily low | 47.40 |
| Daily Volume | 62K |
| All-time high | 179.00 |
| 1y analyst estimate | 47.70 |
| Beta | 0.70 |
| EPS (TTM) | -8.01 |
| Dividend per share | 0.00 |
| Ex-div date | 21 Mar 2025 |
| Next earnings date | 20 Feb 2026 |
Downside potential
Loading...
Downside potential data
| BION.SW | S&P500 | |
| Current price drop from All-time high | -72.96% | -0.50% |
| Highest price drop | -85.89% | -19.00% |
| Date of highest drop | 9 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -79.91% | -2.50% |
| Avg time to new high | - | 6 days |
| Max time to new high | 316 days | 89 days |
COMPANY DETAILS
Marketcap
2.64B
Marketcap category
Mid-cap
Description
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Employees
10
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
December 15, 2025
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproli...
November 10, 2025
SCHAFFHAUSEN, Switzerland - September 22, 2025 (NEWMEDIAWIRE) - BB Biotech AG announces that it will be included in the SPI ESG Index of the SIX Swiss Exchange as of today, September 22, 2025. This hi...
September 22, 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
September 9, 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
September 9, 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
September 9, 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
September 9, 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
September 9, 2025